Influenza Pneumonia
Conditions
Interventions
Experimental group:Influenza pneumonia routine treatment combined with aerosol inhalation of heparin, acetylcysteine, budesonide and ipratropium bromide
Control Group:Influenza pneumonia routine treatment
Sponsors
Army Medical Center (Daping hospital), Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-80 years old; 2. At least one of the following aetiological or serologic findings is met: (1). Nasopharyngeal swabs: positive for influenza virus nucleic acid detected by real-time RT-PCR; (2). Bronchoalveolar lavage fluid or sputum sample: metagenomic next-generation high-throughput sequencing (mNGS) positive for influenza virus; (3). Serological test: virus-specific IgM antibody was positive; 3. antiviral treatment with oseltamivir or mabaloxavir within 48 hours after symptom onset or confirmed influenza infection; 4. Chest CT showed characteristic manifestations of viral pneumonia (ground-glass opacity, consolidation, paving stone sign, centrilobular nodules and interlobular septal thickening in both lungs); 5. can tolerate aerosol inhalation therapy; 6. Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. pregnant women; 2. hemoptysis; 3. allergy/intolerance to experimental drugs; 4. severe respiratory failure requiring invasive mechanical ventilation or ICU admission; 5. the presence of tracheotomy and other conditions that cannot cooperate with atomization; 6. patients with coagulation dysfunction (meeting any of the conditions) : (1). Coagulation function showed hypocoagulation state; (2). platelet count <50×10^9/L; (3). Bleeding in skin or other organs; 7. co-infection with pulmonary Aspergillus; 8. complicated with active pulmonary tuberculosis; 9. patients with pulmonary edema due to heart failure; 10. combined with other life-threatening complications, such as severe liver and kidney damage, uncontrolled malignant tumors, etc. 11. patients enrolled in other clinical trials; The researchers considered other reasons not appropriate for clinical trial participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients were studied for one week at the end of the treatment period for the extent of absorption of lung lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate of oxygenation index;Blood routine and inflammatory indicators (white blood cells, neutrophils, lymphocytes, lymphocyte subsets, platelets, C-reactive protein, procalcitonin, serum amyloid protein, interleukin-6, interleukin-8, tumor necrosis factor-a);Influenza virus load;ICU admission rate;mortality rate;Length of stay;Coagulation function (activated partial thromboplastin time, international normalized ratio, D-dimer); | — |
Countries
China
Contacts
Public ContactLi Li
Army Medical Center (Daping hospital), Army Medical University
Outcome results
None listed